Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

NCT04299880 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Oncology

Interventions

DRUG: Napabucasin
DRUG: Nab-paclitaxel
DRUG: Gemcitabine
DRUG: Nivolumab
DRUG: Paclitaxel
DRUG: Irinotecan
DRUG: Leucovorin
DRUG: 5Fluorouracil
DRUG: Bevacizumab

Sponsor

Sumitomo Pharma America, Inc.